Mechanism-based thrombin inhibitors: Design, synthesis, and molecular docking of a new selective 2-oxo-2H-1-benzopyran derivative

Journal of Medicinal Chemistry

Volumn 50, Issue 15, 2007, Pages 3645-3650

  Frédérick, Raphaël ^a,b   Robert, Séverine ^a   Charlier, Caroline ^a   Wouters, Johan ^a   Masereel, Bernard ^a   Pochet, Lionel ^a  

^a UNIVERSITY OF NAMUR   (Belgium)

^b UNIVERSITY OF AUCKLAND   (New Zealand)

Author keywords

[No Author keywords available]

Indexed keywords

2 (N ETHYL 2' OXOACETAMIDE) 5' CHLOROPHENYL ESTER; 2 OXO 2H 1 BENZOPYRAN DERIVATIVE; BENZOPYRAN DERIVATIVE; BLOOD CLOTTING FACTOR 10A; CHYMOTRYPSIN A; ESTER DERIVATIVE; SERINE PROTEINASE; THROMBIN INHIBITOR; UNCLASSIFIED DRUG;

ARTICLE; DRUG DESIGN; DRUG POTENCY; DRUG SELECTIVITY; DRUG STRUCTURE; DRUG SYNTHESIS; ENZYME INHIBITION; MOLECULAR DOCKING; REACTION ANALYSIS; STRUCTURE ACTIVITY RELATION; STRUCTURE ANALYSIS;

BENZOPYRANS; COUMARINS; DRUG DESIGN; MODELS, MOLECULAR; STRUCTURE-ACTIVITY RELATIONSHIP; THROMBIN;

EID: 34547568454     PISSN: 00222623     EISSN: None     Source Type: Journal    
DOI: 10.1021/jm061368v     Document Type: Article

References (20)

1. Hirsh, J.; O'Donnell, M.; Weitz, J. l. New anticoagulants. Blood 2005, 105 (2), 453-463.
2. Weitz, J. I. New anticoagulants for treatment of venous thromboembolism. Circulation 2004, 110 (9), 119-126.
3. De Simone, G.; Menchise, V.; Omaggio, S.; Pedone, C.; Scozzafava, A.; Supuran, C. T. Design of weakly basic thrombin inhibitors incorporating novel P1 binding functions: molecular and X-ray crystallographic studies. Biochemistry 2003, 42 (30), 9013-9021.
4. Lumma, W. C., Jr.; Witherup, K. M.; Tucker, T. J.; Brady, S. F.; Sisko, J. T.; Naylor-Olsen, A. M.; Lewis, S. D.; Lucas, B. J.; Vacca, J. P. Design of novel, potent, noncovalent inhibitors of thrombin with nonbasic P-1 substructures: rapid structure-activity studies by solid-phase synthesis. J. Med. Chem. 1998, 41 (7), 1011-1013.
5. Sanderson, P. E.; Stanton, M. G.; Dorsey, B. D.; Lyle, T. A.; McDonough, C.; Sanders, W. M.; Savage, K. L.; Naylor-Olsen, A. M.; Krueger, J. A.; Lewis, S. D.; Lucas, B. J.; Lynch, J. J.; Yan, Y. Azaindoles: moderately basic P1 groups for enhancing the selectivity of thrombin inhibitors. Bioorg. Med. Chem. Lett 2003, 13 (5), 795-798.
6. Scozzafava, A.; Briganti, F.; Supuran, C. T. Protease inhibitors. Part 3. Synthesis of non-basic thrombin inhibitors incorporating pyridinium- sulfanilylguanidine moieties at the P1 site. Eur. J. Med. Chem. 1999, 34 (11), 939-952.
7. Supuran, C. T.; Scozzafava, A.; Brigand, F.; Clare, B. W. Protease inhibitors: synthesis and QSAR study of novel classes of nonbasic thrombin inhibitors incorporating sulfonylguanidine and O-methylsulfonylisourea moieties at P1. J. Med. Chem. 2000, 43 (9), 1793-1806.
8. Tucker, T. J.; Brady, S. F.; Lumma, W. C.; Lewis, S. D.; Garden, S. J.; Naylor-Olsen, A. M.; Yan, Y.; Sisko, J. T.; Stauffer, K. J.; Lucas, B. J.; Lynch, J. J.; Cook, J. J.; Stranieri, M. T.; Holahan, M. A.; Lyle, E. A.; Baskin, E. P.; Chen, I. W.; Dancheck, K. B.; Krueger, J. A.; Cooper, C. M.; Vacca, J. P. Design and synthesis of a series of potent and orally bioavailable noncovalent thrombin inhibitors that utilize nonbasic groups in the P1 position. J. Med. Chem. 1998, 41 (17), 3210-3219.
9. Pochet, L.; Doucet, C.; Schynts, M.; Thierry, N.; Boggetto, N.; Pirotte, B.; Jiang, K. Y.; Masereel, B.; de Tullio, P.; Delarge, J.; Reboud-Ravaux, M. Esters and amides of 6-(chloromethyl)-2-oxo-2H-1-benzopyran-3-carboxylic acid as inhibitors of alpha-chymotrypsin: significance of the "aromatic" nature of the novel ester-type coumarin for strong inhibitory activity. J. Med. Chem. 1996, 39 (13), 2579-2585.
10. Frederick, R.; Robert, S.; Charlier, C.; de Ruyck, J.; Wouters, J.; Pirotte, B.; Masereel, B.; Pochet, L. 3,6-Disubstituted coumarins as mechanism-based inhibitors of thrombin and factor Xa. J. Med. Chem. 2005, 48 (24), 7592-7603.
11. Silverman, R. B. Mechanism-based enzyme inactivators. Methods Enzymol. 1995, 249, 240-283.
12. Doucet, C.; Pochet, L.; Thierry, N.; Pirotte, B.; Delarge, J.; Reboud-Ravaux, M. 6-Substituted 2-oxo-2H-1-benzopyran-3-carboxylic acid as a core structure for specific inhibitors of human leukocyte elastase. J. Med. Chem. 1999, 42 (20), 4161-4171.
13. Pochet, L.; Doucet, C.; Dive, G.; Wouters, J.; Masereel, B.; Reboud-Ravaux, M.; Pirotte, B. Coumarinic derivatives as mechanism-based inhibitors of alpha-chynotrypsin and human leukocyce elastase. Bioorg. Med. Chem. 2000, 8 (6), 1489-1501.
14. Pochet, L.; Dieu, M.; Frédérick, R.; Murray, A. M.; Kempen, I.; Pirotte, B.; Masereel, B. Investigation of the inhibition mechanism of coumarins on chymotrypsin by mass spectrometry. Tetrahedron 2003, 59, 4557-4561.
15. Jones, G.; Willett, P.; Glen, R. C.; Leach, A. R.; Taylor, R. Development and validation of a genetic algorithm for flexible docking. J. Mol. Biol. 1997, 267 (3), 727-748.
16. Sybyl, version 7.2.3; Tripos Inc. (1699 South Hanley Rd, St. Louis, MO, 63144).
17. Teague, S. J. Implications of protein flexibility for drug discovery. Nat. Rev. Drug Discovery 2003, 2 (7), 527-541.
18. DeLano, W. L. The PyMOL Molecular Graphics System; DeLano Scientific: San Carlos, CA, 2002.
19. Perola, E.; Walters, W. P.; Charifson, P. S. A detailed comparison of current docking and scoring methods on systems of pharmaceutical relevance. Proteins 2004, 56 (2), 235-249.
20. Erickson, J. A.; Jalaie, M.; Robertson, D. H.; Lewis, R. A.; Vieth, M. Lessons in molecular recognition: the effect of ligand and protein flexibility on molecular docking accuracy. J. Med. Chem. 2004, 47, 45-55.